articleJournal of the American Chemical SocietySep 30, 2014Closed access

Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation

EMEmma M. Pelegri-O’DayELEn‐Wei LinHDHeather D. Maynard

California NanoSystems Institute · University of California, Los Angeles

PubMed
Indexed incrossrefpubmed

Abstract

Protein-polymer conjugates are widely used as therapeutics. All Food and Drug Administration (FDA)-approved protein conjugates are covalently linked to poly(ethylene glycol) (PEG). These PEGylated drugs have longer half-lives in the bloodstream, leading to less frequent dosing, which is a significant advantage for patients. However, there are some potential drawbacks to PEG that are driving the development of alternatives. Polymers that display enhanced pharmacokinetic properties along with additional advantages such as improved stability or degradability will be important to advance the field of protein therapeutics. This perspective presents a summary of protein-PEG conjugates for therapeutic use and…

Citation impact

615
total citations
FWCI
27.85
Percentile
100%
References
119
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • PEGylation
  • Chemistry
  • Conjugate
  • PEG ratio
  • Ethylene glycol
  • Polymer
  • Combinatorial chemistry
  • Drug
No related works found for this paper.

Funding